Poster ecim 2011.cdr

Evidence for efficacy and effectiveness of the MORA Bioresonance method in smoking cessation
Poster presented during 4 European Congress for Integrative Medicine - Berlin, October 07 - 08 in 2011 Ersal Isik, Clinic Neosante, Bahariye cad. 77, 9-10 Kadikoy Istanbul, Turkey, Telephone: +90 2164 506020, e-mail: Galle, Institut für Biophysikalische Medizin, Algenrodter Str. 51a, 55743 Idar-Oberstein, Germany, Telephone: +49 6781 980622, e-mail: IntroductionFor more than thirty years MORA bioresonance therapy (classical bioresonance therapy) is used by naturopathic practitioners all over the world for a broad range of indications (e.g. allergic diseases, rheumatic diseases). The bioresonance method is based on the discoveries of Franz Morell and Erich Rasche [1-3].
At clinical level, a lot of positive studies pertaining to several indication fields have been conducted by international work groups [e.g. 4-12]. Ultra low, coherent, low frequency (1 Hz - 10^5 Hz – range) electromagnetic oscillations are postulated as transmitters of information at a biophysical level [1-3]. However, three clinical studies [13-15] did not confirm the therapeutic effectiveness of the bioresonance method according to the author`s conclusions, so that a continuous controversial discussion is under way [e.g. 16-18]. For further clinical verification of the bioresonance method two studies with one indication, but different methodological test concepts were carried out: 1. Since 2007 until today (2011) one of the authors (EI) applies this therapy concept in his clinic for smoking cessation, and assesses its practical effectiveness at the same time [19]. 2. Over the course of one year (2008 until 2009) Pihtili et al. 2009 [20] verified in a clinical trial the efficacy of the MORA bioresonance method for smoking cessation as well. None of the scientists in this study had any previous experience regarding the device's use and respective method.
These studies are worldwide the first ones which verify the efficacy The study of EI [19] in his clinic was carried out retrospective, Table 1 shows the results of the study. The rate of smoking (by a randomised, double blind placebo trial) and the effectiveness uncontrolled and non selective (including the drop outs). It is cessation after one week was 80.1%, after one month 62.1% and (by practice experience) of the bioresonance method in smoking called “non controlled study” in the following passages.
after three months 48.2% including the drop outs in the cessation. There were no side effects identified, related to the The study of Pihtili et al. [20] (Faculty of Medicine of the calculation (see table 2). No side effects were observed.
practice of this method, like in all other published bioresonance University of Istanbul, Department of Pulmonary Diseases) was carried out prospective, randomised, placebo controlled and Table 1: Rates of smoking cessation as a function of the time double blind. It is called “placebo controlled study” in the period after treatment in the non controlled study with 4733 Regarding the results of the placebo controlled study the participants (number of participants, absolute and relative in application of the active bioresonance is successful and differs significantly and noticeably from the sham bioresonance (see table 2). Comparing the 28.6% success rate of the bioresonance In both studies the indication was smoking. The participants method at the end of the first year with the most effective methods on pharmacological level (varenicline, bupropion), the most effective medicament varenicline (see below) shows similar results but side effects like nausea and insomnia and even partly severe In both studies the participants were treated with the side effects (e.g. attempted suicides), so that 2009 a warning had bioresonance method by use of the MORA-Super device (Med- been announced by the FDA. A lot of studies were conducted with Tronik GmbH, Friesenheim/Baden, Germany) in a similar way. the above mentioned medicaments. For example Oncken et al. A smoking specific bioresonance treatment was conducted one 2006 [21] using varenicline and bupropion documented the time by placing smoked cigarettes in the input electrodes. 18% following success rates after one year: 23.0% for varenicline, of the participants in the non controlled study got a support 14.6% for bupropion and 10.3% for placebo. The three treatment shortly after their first treatment while 16.7% received Seven days after the bioresonance treatment the probands were treatments differ significantly. These results are typical for many questioned as to whether they felt that the treatment had reduced other studies. According to the meta-analyses of Eisenberg et al. Furthermore in both studies the anti-smoking information was their desire to smoke. 95.8% perceived the treatment as effective, 2008 [22] on a pharmacological level the most successful results transferred to a liquid of 92% serum physiological with 8% ethyl 3.8% felt no effect at all and 0.4% were not contactable by phone.
alcohol as well as to a chip. The chip had to be worn below the navel for one month while the liquid should be used if the After 3 months the uncontrolled study showed a success rate of The effectiveness research test at the end of the first week 48.2% with the bioresonance method (see table 1). Regarding this revealed, that the urge to smoke in the bioresonance group time period Jorenby et al. 2006 [23] reported 43.9% in the Assessment, main outcome and observation time decreased significantly compared to the placebo group, varenicline group and 29.8% in the buproprion group. Gonzales The probands in the non controlled study were interviewed by respectively in the first three days (p = 0.002) and the second et al. 2006 [24] documented a success rate of 44.0% for telephone regarding their smoking habit (main outcome: quitting three days (p = 0.003). The rate of smoking without any varenicline and 29.5% for bupropion. Also on a three month smoking) at certain intervals (after one week, one month and discomfort in the bioresonance group was significantly lower observation period, the success rate of the bioresonance method is three months). On the third day after the first treatment they were compared to the placebo group (p = 0.003). Individuals from the similar to the best pharmacological results. questioned whether they needed a support treatment (still a bioresonance group did not feel the urge to smoke in a smoking The remarkable thing about it is that no side effects were observed strong desire for smoking) or a second full treatment (they were environment (p = 0.005) and overall showed no signs of irritation in both bioresonance studies which stands in clear contrast to the (p = 0.005). In comparison with 24.7% of the participants in the pharmacological studies. In this context it is important to say that In the placebo controlled study the probands were questioned placebo group (p = 0.01), 48.0% in the bioresonance group the above mentioned medicaments were taken daily during the regarding their smoking habit as well (main outcome: quitting stated, that the drops administered following the treatment session whole observation intervals, even when the results were calculated, smoking) at certain intervals (after one week, two weeks, one reduced the urge to smoke. The participants of the bioresonance whereas in the bioresonance treatment only one or maximal a few month and one year). A questionnaire was given to them with group which stated that the treatment was effective were treatment sessions at the beginning were carried out and the the objective to determine the effectiveness of the method at the significantly higher than in the placebo group (p < 0.001). Table probands continued their life without any medicaments which 2 shows the rates of smoking cessation. Also in this study no side might have fairly often side effects, even partly in a serious Information was also gathered on the participant's Fagerström Nicotine Dependence Score, previous experience of quitting smoking and psychological treatment anamnesis. Table 2: Rates of quitting smoking in the bioresonance and As mentioned in the introduction, further clinical studies confirm placebo groups (number of participants, absolute and relative in the clinical effectiveness of bioresonance therapy in a broad range of indications [e.g. 4-12]. Therefore these results in smoking The non controlled study included 4733 participants (2068 cessation are no exception on a clinical research level of the females, 2665 males). 60.8% were between the age of 30 and bioresonance method. Even a lot of investigations with animals 50, 19.0% above 50. 44.2% had been smoking between 10 and plants give evidence for the efficacy of bioresonance method and 20 years and 42.1% for more than 20 years. 34.4% had smoked 11-20 and 37.0% 21-30 cigarettes daily. According to On a physical level Korenbaum et al. 2006 [29] showed in a the Fagerström scale 60.1% had a high or very high addiction.
randomized and double blind trial that electronic copies of The placebo controlled study included 95 probands (53 females, bioactive substances, using the bioresonance method, are different 42 males) in the active bioresonance group and 94 (60 females from placebo electronic copies in the absorption spectra in the One month 46 (51.1%) 26 (28.6%) p = 0.002 and 34 males) in the placebo bioresonance group. The two optical frequency range from 700 to 800 nm. Montagnier et al. groups were statistically equal (p > 0.05) in demographic 2009 [30] detected electromagnetic oscillations in the low characteristics (gender, age, occupation) and smoking frequency range (about 1000 Hz) with an experimental anamnesis (number of cigarettes smoked daily, number of years In every time period after treatment the rate of smoking cessation construction which was a copy of the exogenous part of the smoking). About 65% of the participants of the two groups were in the bioresonance group was significantly and noticeably higher 30 to 50 years old, ca. 20% above 50. About 60% had been than in the placebo group (see table 2).
The broad spectrum of indications and the general biological smoking for more than 20 years, approximately 55% smoked efficiency in connection with the ability of electromagnetic storing 11-20 and approx. 25% 21-30 cigarettes daily.
of the specific biological and clinical information points to a fundamental biophysical mechanism of effectiveness on the electromagnetic level [see 3].
17. Classen M.: Kuhmilchinduzierte Enteropathie – Diagnostik durch Bioresonanz? Pädiatrische Praxis 2007; 70(4):612-614.
18. Kleine-Tebbe J, Ballmer-Weber B, Beyer K, et al.: In-vitro-Diagnostik und molekulare Grundlagen von IgE-vermittelten Nahrungsmittelallergien. Allergo Journal 2009; 18(2): 132-146.
1. Morell F: MORA-Therapie – patienteneigene und Farblicht-schwingungen. Heidelberg, Haug 1987.
19. Isik ES: MORA bioresonance method (MORA-Therapy) to quit smoking. Clinical report 2011, Clinic Neosante, Istanbul, Turkey.
2. Herrmann E: Das MORA-Praxisbuch – Therapie mit körpereigenen Schwingungen. Haug, Heidelberg 1998.
20. Pihtili A, Cuhhadraroglu C, Kilicaslan Z, Issever H, Erkan F: The effectiveness of bioresonance method in quitting smoking. Clinical report 2009, Department of Medicine, University 3. Galle M: MORA-Bioresonanztherapie.und es funktioniert doch! Biologische Fakten -Physikalische Thesen. Wiesbaden, Pro-medicina 2002.
Istanbul, Turkey (in preparation for publication).
4. Maiko OJu, Gogoleva EF: Outpatient bioresonance treatment of gonarthrosis. Terapevticheskii Arkhiv 2000; 72 (12):50-53.
21. Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, Anziano R, Reeves K: Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, 5 Gogoleva EF: New approaches to diagnosis and treatment of fibromyalgia in spinal osteo-chondrosis. Ter Arkh 2001; 73: 40-45.
varenicline, for smoking cessation. Arch Intern Med 2006; 166(15):1571-1577.
6. Yang J, Zhang L: 300 Behandlungsbeispiele gegen Asthma mittels BICOM-Grätes für die Kinderpatienten. Maternal and Child Health Care of China 2004; 19(9):126-127.
22. Eisenberg MJ, Filion KB, Yavin D, Belisle P, Mottillo S, Joseph L, Gervais A, O`Loughlin J, Paradise G, Rinfret S, Pilote L: Pharmacotherapies for smoking cessation: a meta-analysis of Two methodologically complementary studies show evidence for 7. Huang S, Sun Z, Fang Y: Klinische Behandlung vom allergischen Schnupfen und Bronchialasthma der Kinder mit dem Bioresonanztherapiegerät. Zhejiang Medical Journal 2005; randomized controlled trials. CAMJ 2008; 179(2):135-144.
23. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR: Varenicline Phase 3 StudyGroup: Efficacy of varenicline, an alpha4beta2 nicotinic 8. Nienhaus J, Galle M: Placebokontrollierte Studie zur Wirkung einer standardisierten MORA Bioresonanztherapie auf funktionelle Magen-Darm-Beschwerden. Forschende acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296(1):56-63.
significant and noticeable efficacy respectively a high practical 24. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR; Varenicline Phase 3 Study Group.Varenicline, an alpha4beta2 9. Rahlfs VW, Rozehnal A: Wirksamkeit und Verträglichkeit der Bioresonanzbehandlung. Erfahrungsheilkunde 2008; 57(8):462-468. nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296(1):47-55.
10. Schuller J., Galle M.: Untersuchung zur Prüfung der klinischen Wirksamkeit elektronisch abgespeicherter Zahn- und Gelenksnosoden bei Erkrankungen des Rheumatischen Formen- 25. Hutzschenreuter P Brümmer H: Die Narbe, das Keloid und die MORA-Therapie. Therapeutikon 1991; 5 (10):507-515. effectiveness of the MORA bioresonance therapy in smoking kreises. Forsch. Komplementärmed. 2007; 14:289-296.
26. Endler PC, Heckmann C, Lauppert E, Pongratz W, Smith CW, Senekowitsch F, Citro M: Amphibienmetamorphose und Information von Thyroxin. Speicherung durch bipolare Flüssigkeit 11. Chen T, Guo ZP, Zhang YH, Gao Y: Effect of MORA bioresonance therapy in the treatment of Henoch-Schonlein purpura and influence on serum antioxidant enzymes. Journal of Wasser und auf technischen Datenträger; Übertragung von Information durch elektronischen Verstärker. In: P C Endler und J Schulte (Hrsg.): Homöopathie – Bioresonanztherapie: 127- Clinical Dermatology 2010; 39(5):283-285.
12. Herrmann E, Galle M: Retrospective surgery study of the therapeutic effectiveness of MORA bioresonance therapy with conventional therapy resistant patients suffering from allergies, 27. Fedorowski A, Steciwko A, Rabczynski J: Low-frequency electromagnetic stimulation may lead to regression of Morris Hepatoma in Buffalo rats. The Journal of Alternative and pain and infection diseases. Accepted for publication in June 2011 in European Journal of Integrative Medicine.
Complementary Medicine 2004: 10(2):251-260.
13. Kofler H, Ulmer H, Mechtler E, Falk M, Fritsch PO: Bioresonanz bei Pollinose – eine vergleichende Untersuchung zur diagnostischen und therapeutischen Wertigkeit. Allergologie 28. Thomas Y, Kahhak L, Aissa J: The physical nature of the biological signal, a puzzling phenomenon: the critical contribution of Jaques Benveniste. In: G.H. Pollack, I.L. Cameron, D.N. Wheatley (ed.): Water and the cell: 325-340, Springer, Dordrecht, Netherlands 2006. 14. Schöni MH, Nikolaizik WH, Schöni-Affolter F: Efficacy Trial of Bioresonance in Children with atopic dermatitis. International Archives of Allergy and Immunology 1997; 112: 238-246.
29. Korenbaum VI, Chernysheva TN, Apukhtina TP, Sovetnikova LN: Absorption spectra of electronic-homoeopathic copies of homoeopathic nosodes and placebo have essential 15. Wille A: Bioresonanztherapie (biophysikalische Informationstherapie) bei stotternden Kindern. Forschende Komplementärmedizin 1999; 6, Suppl. 1:50-52.
differences. Forschende Komplementärmedizin 2006; 13:294-297.
16. Wüthrich B, Frei PC, Bircher A, et al.: Bioresonanz – diagnostischer und therapeutischer Unsinn. Schweizerische Ärztezeitung 2006; 87:50-54.
30. Montagnier L, Aissa J, Ferris S, Montagnier J-J, Lavallee C: Electromagnetic signals are produced by aqueous nanostructures derived from bacterial DNA sequences. Interdisciplinary Sciences: Computational Life Sciences 2009; 1:81-90.


Microsoft word - press release 29th april 2013

EryDel announces US IND approval for EryDex Urbino, Italy – April 29 - EryDel SpA (, a Drug Delivery Company specialized in the development of drugs and diagnostics delivered through red blood cells (RBCs), announced today that it has received approval to start its first study in the US. The Investigational New Drug (IND) Application for EryDex (Dexamethasone Sodium Phosphate

Science magazine

R E S E A R C H A N D D E V E LO P M E NT Where Is the New Science most new science in developed rather thandeveloping economies for reasons that may not in Corporate R&D? always characterize the U.S. situation. Jerry Thursby and Marie Thursby* The idea that the United States domi- or currently planned R&D facility both views of corporate R&D. For example,outside and inside

Copyright 2014 Pdf Medic Finder